Recombinant Trivalent Influenza Vaccine (Flublok®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults

Flublok ® is a trivalent influenza vaccine manufactured using the baculovirus-insect cell system, which has a number of differences compared with the traditional embryonated chicken egg system. Flublok ® is the first vaccine containing recombinant protein to be approved for the prevention of seasona...

Full description

Saved in:

Bibliographic Details
Published in:	Drugs (New York, N.Y.) N.Y.), 2013-08, Vol.73 (12), p.1357-1366
Main Author:	Yang, Lily P. H.
Format:	Article
Language:	eng
Subjects:	Adis Drug Evaluation Adolescent Adult Age groups Aged Antibodies Biological and medical sciences Disease prevention Eggs Human viral diseases Humans Immunization Infectious diseases Influenza Influenza Vaccines - administration & dosage Influenza, Human - prevention & control Internal Medicine Medical sciences Medicine Medicine & Public Health Middle Aged Older people Pharmacology/Toxicology Pharmacotherapy Proteins Randomized Controlled Trials as Topic Seasons United States United States Food and Drug Administration Vaccination - methods Vaccines Viral diseases Viral diseases of the respiratory system and ent viral diseases Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Flublok ® is a trivalent influenza vaccine manufactured using the baculovirus-insect cell system, which has a number of differences compared with the traditional embryonated chicken egg system. Flublok ® is the first vaccine containing recombinant protein to be approved for the prevention of seasonal influenza, and is indicated in the USA in adults aged 18–49 years. In a large, placebo-controlled, phase III trial in individuals aged 18–49 years, Flublok ® met the US FDA requirements for immunogenicity, effectiveness and safety, despite a high incidence of antigenic mismatch between confirmed cases of influenza and the vaccine component strains. Flublok ® was also compared with Fluzone ® in two noninferiority trials in older adults aged 50–64 or ≥65 years; although noninferiority was shown for a number of endpoints in these trials, Flublok ® is not currently approved in these age groups. Flublok ® is a useful and generally well-tolerated vaccination option for the prevention of seasonal influenza in adults aged 18–49 years, including those with egg allergy.
ISSN:	0012-6667 1179-1950